Overcoming Resistance Mechanisms with NUZYRA

NUZYRA (omadacycline) is a key product developed by Paratek Pharmaceuticals. It is a new antibiotic that was approved by the US FDA in 2018 for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). NUZYRA is a once-daily, broad-spectrum antibiotic that is administered both orally and intravenously, making it a versatile option for treating infections in a variety of settings, including hospitals, clinics, and at home.

One of the key features of NUZYRA is its ability to overcome the resistance mechanisms that bacteria have developed against other antibiotics. It is the first tetracycline-class antibiotic to be approved in over 20 years, and it is structurally distinct from other antibiotics in its class, making it a valuable tool in the fight against antibiotic resistance.

Playing Significant Role in Treating Bacterial Infections

NUZYRA’s effectiveness has been demonstrated in clinical trials, where it was shown to be non-inferior to other antibiotics commonly used to treat CABP and ABSSSI. In addition, NUZYRA was shown to be well-tolerated by patients, with a low incidence of adverse events.

As a result of its unique features and demonstrated efficacy, the antibiotic has the potential to play a significant role in treating serious bacterial infections, particularly those caused by antibiotic-resistant organisms. Paratek Pharmaceuticals is continuing to explore the potential of NUZYRA through ongoing research and development efforts, with the goal of expanding its indications and helping more patients in need.

Passion for Innovation and Deep Understanding of Healthcare Industry

Evan Loh is the Chief Executive Officer (CEO) of Paratek Pharmaceuticals. With a passion for innovation and a deep understanding of the healthcare industry, Loh has been instrumental in the development of NUZYRA, Paratek’s key product. In addition, he is a seasoned pharmaceutical executive with over 20 years of experience in the industry. Prior to joining Paratek, he held various leadership roles at pharmaceutical companies such as Pfizer, Wyeth, and AstraZeneca. Loh’s expertise spans multiple therapeutic areas, including infectious diseases, oncology, and respiratory medicine.

One of Loh’s key priorities at Paratek is to advance the development of new antibiotics to combat the growing threat of antibiotic resistance. In his own words, “We have to stay ahead of the innovation curve and bringing new research and development opportunities forward in order to provide new antibiotics.” Under Loh’s leadership, Paratek has been at the forefront of antibiotic research and development, working to bring new and innovative treatments to patients in need.

Loh’s commitment to advancing healthcare and improving patient outcomes has earned him widespread recognition in the industry. He has been honored as one of the PharmaVOICE 100 Most Inspiring People in the Life-Sciences Industry, and he serves on the board of the Biotechnology Innovation Organization (BIO), a leading trade association for the biotechnology industry.

Embrace Sustainability across Operations

Paratek Pharmaceuticals has taken several steps to embrace sustainability across its operations, from research and development to commercialization. One of the company’s key focuses is reducing its environmental impact. To achieve this, Paratek has implemented initiatives such as green chemistry practices, reducing the use of hazardous materials, and optimizing waste management practices. The company also strives to minimize its carbon footprint by reducing energy consumption, using renewable energy sources where possible, and implementing energy-efficient technologies in its facilities.

In addition to environmental sustainability, Paratek is also committed to social and ethical sustainability. The company ensures that its supply chain partners adhere to its ethical and social responsibility policies, and it maintains a diverse and inclusive workforce. Through its commitment to sustainability, Paratek aims to create long-term value for its stakeholders while contributing to a more sustainable future.

Chronicles of Success

Paratek Pharmaceuticals has achieved several notable accomplishments that reflect its commitment to innovation and improving patient outcomes. In 2019, the company was awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA) to support the development of NUZYRA for the treatment of anthrax. This collaboration underscores the potential of NUZYRA to address significant public health threats.

In addition, Paratek has a strong pipeline of potential new antibiotics and other innovative treatments in various stages of development. These efforts highlight the company’s ongoing commitment to research and development and its potential to make a significant impact in the healthcare industry.

As the company continues to explore new treatment options and advance its pipeline, it is well-positioned to be a leading independent biopharmaceutical company, providing novel life-saving products for life-threatening diseases or other public health threats.